Neuroendocrine Tumours

• Thoracic neuroendocrine tumors
• Thymic large cell neuroendocrine carcinoma- a rare and aggressive tumor: case report
• Primary Neuroendocrine Tumor of the Maxilla: A Case Report
• Efficacy of chemotherapy for elderly patients with extrapulmonary neuroendocrine carcinomas
• A study of efficacy and safety with apatinib therapy in advanced neuroendocrine carcinoma patients
• Participant Clinical Case Discussion: Metastatic Prostate Cancer with Neuroendocrine Differentiation
• Participant Clinical Case Discussion: A Case Report of Prostatic Acinar Adenocarcinoma with Neuroendocrine Differentiation
• Congress Highlights 2 - NETs and endocrine tumours
• State of the art management of GEP- NET - Pathological diagnosis: What is important for the clinician?
• State of the art management of GEP- NET - Therapeutic approaches for syndrome management
• State of the art management of GEP- NET - Therapeutic approaches for tumour growth control
• Efficacy of Lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Result...
• Proffered paper session - NETs and endocrine tumours - Invited Discussant 1307O
• Activity & Safety of Spartalizumab (PDR001) in Patients (pts) With Advanced Neuroendocrine Tumors (NET) of Pancreatic (Pan), Gastrointestinal (GI),...
• Efficacy and safety of PD-1 blockade with JS001 in patients with advanced neuroendocrine neoplasms: a non-randomized, open-label, phase 1b trial
• Proffered paper session - NETs and endocrine tumours - Invited Discussant 1308O and 1309O
• Clinico-genomic profiling and outcome prediction of neuroendocrine prostate cancer (NEPC)
• Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate (NEPC)
• Neuroendocrine carcinoma of the urinary bladder: a large analysis of the French GETUG consortium
• Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms
• Poster Discussion session - NETs and endocrine tumours - Invited Discussant 450PD and 1310PD
• Health-related quality of life (HRQoL) for octreotide long-acting (oct l-a) vs. placebo (PBO) in patients (pts) with metastatic midgut neuroendocri...
• Everolimus after transarterial liver therapy of metastases from gastrointestinal neuroendocrine tumors: the FFCD 1104-EVACEL-GTE phase II study
• A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-contained che...
• Poster Discussion session - NETs and endocrine tumours - Invited Discussant 1311PD, 1312PD and 1313PD

• « Previous
• 1
• 2
• ...
• 14
• Next »